Subcutaneous · Glucagon receptor agonist
Dasiglucagon
24 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
24
Ongoing
0
Recruiting
0
Completed
21
Sites
51
Countries
10
Endpoints
491
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Early Phase 1
1
Phase 1
4
Phase 2
9
Phase 2/3
2
Phase 3
8
Trials by status
Completed
21
Withdrawn
3
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
228
Glycemic / diabetes
148
Other (unclassified)
108
Cardiometabolic biomarkers
4
Patient-reported / QoL
3
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
24 of 24
Showing 1-24 of 24 trials